Key facts
- This page summarizes Thomas Watkins's Form 4 filing for Vanda Pharmaceuticals Inc. (VNDA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2022, 16:31.
Thomas Watkins - 02 Jun 2022 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)
- Reporting relationship
- Director
- Issuer ticker
- VNDA
- Reported as of
- 02 Jun 2022
- Net transaction value
- -$1,529
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2022, 16:31:07 UTC
- Prior SEC filing
- 02 May 2022
- Next SEC filing
- 02 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ H. Thomas Watkins
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Watkins filed Form 4 for Vanda Pharmaceuticals Inc. (VNDA) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 02 May 2022.
- Current net transaction value: -$1,529.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VNDA
transaction
Common Stock
Options Exercise
- Transaction value
- $62,250
- Shares
- +15,000
- Change %
- +28%
- Price
- $4.15
- Shares after
- 69,505
- Date
- 02 Jun 2022
- Ownership
- Direct
VNDA
transaction
Common Stock
Sale
- Transaction value
- $63,779
- Shares
- -6,441
- Change %
- -9.3%
- Price
- $9.90
- Shares after
- 63,064
- Date
- 02 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VNDA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $4.15
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 13, 2022 as reflected in this Form 4.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $9.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Footnote F3
The option vested in 12 equal monthly installments beginning on July 14, 2012.